SI-BONE To Report Third Quarter Financial Results on November 29, 2018


SANTA CLARA, Calif.,  /PRNewswire/ -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company that is pioneering the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced it will report financial results for the third quarter of 2018 after market close on Thursday, November 29, 2018. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Thursday, November 29, 2018.

Investors interested in listening to the conference call may do so by dialing (866) 470-1968 for U.S. callers or (409) 217-8248 for international callers (Conference ID: 1083139). The webcast can be accessed at

Within 24 hours of the webcast, a replay will be available by clicking on the Events link at

About SI-BONE, Inc. 
SI-BONE is a medical device company that pioneered the iFuse Implant System, a minimally invasive surgical system for fusion of the sacroiliac joint to treat sacroiliac joint dysfunction.  The SI joint is believed to be the last major joint with a clinically proven surgical treatment.  The iFuse Implant, commercially available since 2009, is believed to be the only SI joint fusion device supported by multiple prospective clinical studies showing improved pain, patient function and quality of life resulting from treatment.  There are over 60 peer-reviewed publications supporting the safety, effectiveness, and biomechanical and economic benefits unique to the iFuse Implant.  This body of evidence has enabled multiple government and private payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.

SI-BONE iFuse Logo. (PRNewsFoto/SI-BONE, Inc.)



Cision View original content to download multimedia:


Company Codes: NASDAQ-NMS:SIBN

Back to news